NOVEL THERAPIES FOR INFLAMMATORY DISEASES THAT DEPEND ON
NLRP3 INFLAMMASOME ACTIVITY
OUR SCIENCE
Apaxen is developing innovative treatments for patients with diseases that depend on chronic NLRP3 Inflammasome activation, via targeting a new mechanism of action.
Macrophage Migration Inhibitor Factor(MIF) was recently identified to play a key role in the intracellular assembly of the NLRP3 inflammasome. Inhibiting this mechanism prevents disease-causing downstream effects of the NLRP3 inflammasome.
By targeting this mechanism and other aspects of MIF biology, Apaxen’s platform allows for the development of novel treatments for many inflammatory, autoimmune and inflammaging-related diseases
PIPELINE
Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 Inflammasome activation and MIF.
